TransCode publishes preclinical RIG-I agonist data in Molecular Imaging and Biology

Transcode Therapeutics, Inc.

Manuscript published Feb 19, 2026 in Molecular Imaging and Biology.
Novel template-driven RIG-I agonist activates innate immunity selectively in tumor cells.
Uses overexpressed miRNA-21 as intracellular assembly template; aims to reduce systemic toxicity.
Study conducted with Prof. Anna Moore (Michigan State Univ.) and TransCode CSO Zdravka Medarova.
TTX nanoparticle delivery platform underpins the approach; currently in clinical trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.